Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaimal Kothari

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Current Opinion in Supportive and Palliative Care|April 23, 2024
Supportive care measures for bispecific T-cell engager therapies in haematological malignanciesLucia Y Chen, Jaimal Kothari
Ejhaem|July 18, 2022
Acquired platelet dysfunction in newly diagnosed myelomaJoshua Mortimer, Nicola Gray, Michael Desborough, et al.
Plos One|December 13, 2018
Clinical outcomes of bortezomib-based therapy in myelomaFaouzi Djebbari, Anandagopal Srinivasan, Grant Vallance, et al.
Blood Advances|August 15, 2019
Pathophysiology and management of monoclonal gammopathy of renal significanceAnkur Jain, Richard Haynes, Jaimal Kothari, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 9, 2019
Resource implications of bortezomib therapy in a large UK cohort: An evaluation studyFaouzi Djebbari, Maciej Tatarczuch, Fotios Panitsas, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 28, 2020
Hematologic Markers and Prostate Cancer Risk: A Prospective Analysis in UK BiobankEleanor L Watts, Aurora Perez-Cornago, Jaimal Kothari, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|December 23, 2021
Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World CohortNadjoua Maouche, Anandagopal Srinivasan, Heather Leary, et al.
Plos One|February 22, 2020
Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patientsFaouzi Djebbari, Faye A Sharpley, Susan McLain-Smith, et al.
British Journal of Haematology|August 8, 2015
Mycophenolate mofetil therapy for severe immune thrombocytopeniaAlice Taylor, Lucy Neave, Shalini Solanki, et al.
British Journal of Haematology|January 12, 2022
Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guidelineGuy Pratt, Dima El-Sharkawi, Jaimal Kothari, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Current Opinion in Supportive and Palliative Care|April 23, 2024
Supportive care measures for bispecific T-cell engager therapies in haematological malignanciesLucia Y Chen, Jaimal Kothari
Ejhaem|July 18, 2022
Acquired platelet dysfunction in newly diagnosed myelomaJoshua Mortimer, Nicola Gray, Michael Desborough, et al.
Plos One|December 13, 2018
Clinical outcomes of bortezomib-based therapy in myelomaFaouzi Djebbari, Anandagopal Srinivasan, Grant Vallance, et al.
Blood Advances|August 15, 2019
Pathophysiology and management of monoclonal gammopathy of renal significanceAnkur Jain, Richard Haynes, Jaimal Kothari, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 9, 2019
Resource implications of bortezomib therapy in a large UK cohort: An evaluation studyFaouzi Djebbari, Maciej Tatarczuch, Fotios Panitsas, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 28, 2020
Hematologic Markers and Prostate Cancer Risk: A Prospective Analysis in UK BiobankEleanor L Watts, Aurora Perez-Cornago, Jaimal Kothari, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|December 23, 2021
Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World CohortNadjoua Maouche, Anandagopal Srinivasan, Heather Leary, et al.
Plos One|February 22, 2020
Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patientsFaouzi Djebbari, Faye A Sharpley, Susan McLain-Smith, et al.
British Journal of Haematology|August 8, 2015
Mycophenolate mofetil therapy for severe immune thrombocytopeniaAlice Taylor, Lucy Neave, Shalini Solanki, et al.
British Journal of Haematology|January 12, 2022
Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guidelineGuy Pratt, Dima El-Sharkawi, Jaimal Kothari, et al.
Pageof 3